Consolidation therapy for AML FLT3-mutated relies on 3–4 cycles of IDAC 1000–1500 mg/m2 IV (500–1000 mg/m2 if ≥60 y old) over 3 h q12h d1-3 plus midostaurin 50 mg q12h PO d8–21 (in all cycles). Here, FLT3 is linked to acute myeloid leukemia.